We describe the case of a 69-year old
male with an EGFR- positive Imatinib refractory
sacral chordoma with synchronous lung metastases,
treated with erlotinib, a first- generation EGFR
inhibitor. After disease progression following firstline Imatinib and a combination therapy with
everolimus plus metformin, we made a challenge
with an EGFR tyrosine kinase inhibitor (EGFR TKI),
erlotinib. Despite a brief clinical benefit, the patient
presented a rapid clinical deterioration leading to
death, after 8 weeks of treatment